Andre Kydd, MD, PhD

Andre Kydd

Assistant Professor, Genitourinary Oncology Program

Areas of Expertise

Testicular Cancer, Bladder Cancer, Prostate Cancer, Urethral Cancer, Adrenal Tumor, Penile Cancer, Ureteral Cancer, Kidney Cancer

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Temple University Hospital - Main Campus
    3401 N. Broad Street
    Philadelphia, PA 19140
    Phone: 800-836-7536

Educational Background

  • Fellowship, Hematology/Oncology, National Institutes of Health/National Cancer Institute
  • Residency, Internal Medicine, Florida Atlantic University, Boca Raton, FL
  • MD, Johns Hopkins University School of Medicine, Baltimore, MD

Honors & Awards

  • Teaching Fellow of the Year Award, 2024-2025
  • Robert A. Winn Excellence in Clinical Trials: Career Development Award (Winn CDA), Cohort 4, 2024-2026
  • Bladder Cancer Advocacy Network (BCAN) John Quale Travel Fellowship A ward for Young Investigators, BCAN Think Tank Annual Conference, 2024
  • ASCO-AACR Methods in Clinical Cancer Research Workshop (aka "Vail Conference") for Clinical Trial Development, 2023
  • Intramural Continuing Umbrella of Research Experiences (iCURE), National Institutes of Health, 2020-2022
  • Medical Scientist Training Program (MSTP) funding for MD/PhD Research (Johns Hopkins University School of Medicine), Baltimore, MD, 2007-2012
  • Chief Resident (PGY3), Florida Atlantic University (FAU) Internal Medicine Residency Program, 2016-2017
  • Magna Cum Laude, Harvard College, Cambridge, MA (Biochemical Sciences), 2004

Selected Publications

  1. Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Ley L, Cordes LM, Steinberg SM, Sierra-Ortiz 0, Cadena J, Diaz C, Costello R, Lee S, Lee M, Rastogi S, Sato N, Cao L, Merino MJ, Bagheri M, Redd B, Gurram S, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Toubaji A, Parnes HL; Ning YM, Dahut WL, Gulley JL, Bottaro DP, Saraiya B, Pal SK, Quinn D, Stein MK, Lara PN, Mortazavi A. Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors. J Clin Oncol. 2024 Sep 1 ;42(25):3033-3046.
  2. Kydd AR, Chandran E, Simon N, Atiq S, Ley L, Wang T, Cordes L, Patel R, Smith E, Boudjadi S, Niglio SA, Yousefi-Rad A, Weng S, Stukes I, Banday AR, Akbulut D, Gurram S, Redd B, Steinberg S, Choo-Wosoba H, Apolo AB. SMART: A Phase 2 Study of Sacituzumab Govitecan (SO) with or without Atezolizumab in Rare Genitourinary (GU) Tumors. [Submitted, Future Oncology]
  3. Kydd AR, Sarwar MS, Atiq S, Chelluri R, Gurram S, Chandran E, Simon N, Stukes I, Weng S, Yousefi-Rad A, Banday AR, Boudjadi S, Apolo AB. Antibody-drug conjugates in rare genitourinary tumors: review and perspectives. Curr Opin Oncol. 2025 Mar 19. doi: 10.1097/CC0.0000000000001141. Epub ahead of print. PMID: 40110990.
  4. Simon N, Kydd AR, Akbulut D, Takeda D, del Rivero J, Merino MJ, Redd B, Lindenberg L, Mena Gonzalez E, Chandran E, Gurram S, Boudjadi S, Niglio S, Sharma P, Thomas A, Apolo AB. Small Cell Carcinoma of the Bladder: Review of Pathogenesis, Presentation, and Management. [Submitted - Bladder Cancer]
  5. Sato N, Lee MJ, Rastogi S, Oubenali N, Lee S, Kydd AR, Apolo AB, Trepel JB. Unraveling the Role of Immune Subsets in Bladder Cancer: A Comprehensive Review. [In preparation]
  6. Kydd AR, Chandran E, Simon N, Apolo AB. Patient and caregiver benefit-risk preferences for treatment of advanced urothelial carcinoma: a discrete choice experiment. [In preparation - J Clin. One. Oncology Practice]
  7. Chandran E, Simon N, Kydd AR, Apolo AB. Oncologist benefit-risk preferences for treatment of advanced urothelial carcinoma: a discrete choice experiment. [In preparation - JCO Oncology Practice]
  8. Chandran E, Simon N, Kydd AR, Apolo AB. Payers' preferences for first-line treatments in advanced urothelial carcinoma: a discrete choice experiment. [In preparation -JCO Oncology Practice]
  9. Jacobsen AA, Kydd AR, Strasswimmer J. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma. J Am Acad Dermatol. 2017 April;76(4):767-8.
  10. Cheng J, Kydd AR, Nakase K, Noonan KM, Murakami A, Tao H, Dwyer M, Xu C, Zhu Q, Marasco WA. Negative regulation of the SH2-homology containing protein-tyrosine phosphatase- I (SHP-1) P2 promoter by the HTL V-1 Tax oncoprotein. Blood. 110(6): 2110-20, Sept, 2007